Cimavax-EGF in Combination with First-Line Chemotherapy in III Stage NSCLC

被引：0
|
作者：
Neninger, E. [1 ]
Caceres, H. [1 ]
Camacho, K. [2 ]
Hernandez, M. [3 ]
Santiesteban, E. [2 ]
Del Castillo, C. [4 ]
Menendez, Y. [4 ]
Gonzalez, B. [5 ]
机构：
[1] Hermanos Ameijeiras Hosp, Clin Oncol, Havana, Cuba
[2] Jose Ramon Lopez Hosp, Clin Oncol, Matanzas, Cuba
[3] Mol Immunol Ctr, Havana, Cuba
[4] Hermanos Ameijeiras Hosp, Radiotherapy, Havana, Cuba
[5] Ramon Lopez Tabranes Hosp, Matanzas, Cuba
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Cimavax Egf vaccine; IIIa NSCLC; immunogenicity;
D O I：
10.1016/j.jtho.2019.08.1435
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-92
引用
收藏
页码：S676 / S677
页数：2
相关论文
共 50 条
  • [41] Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer
    Daan J. Reesink
    Harm H. E. van Melick
    Paul B. van der Nat
    Maartje Los
    Simon Horenblas
    Ewoudt M. W. van de Garde
    World Journal of Urology, 2023, 41 : 1551 - 1562
  • [42] A Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
    Vadehra, Deepak
    Janes, Cayla
    Frascati, Rachel
    Reid, Mary
    Ramos, Tania C.
    Mukherjee, Sarbajit
    Monzon, Kalet L.
    Alvarez, Patricia L.
    Morales, Orestes S.
    Pardillo, Circe M.
    Fountzilas, Christos
    CANCER RESEARCH, 2024, 84 (07)
  • [43] First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC
    Zhou, Caicun
    Solomon, Benjamin
    Loong, Herbert H.
    Park, Keunchil
    Perol, Maurice
    Arriola, Edurne
    Novello, Silvia
    Han, Baohui
    Zhou, Jianying
    Ardizzoni, Andrea
    Mak, M. Perez
    Santini, Fernando C.
    Elamin, Yasir Y.
    Drilon, Alexander
    Wolf, Juergen
    Payakachat, Nalin
    Uh, Minji K.
    Rajakumar, Deborah
    Han, Hongmei
    Puri, Tarun
    Soldatenkova, Victoria
    Lin, A. Bence
    Lin, Boris K.
    Goto, Koichi
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (20): : 1839 - 1850
  • [44] Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC?
    Zheng, Yulong
    Xu, Nong
    Zhou, Jianying
    LANCET ONCOLOGY, 2013, 14 (11): : E438 - E438
  • [45] Clinical characteristics of KRAS mutations in NSCLC and their impact on outcomes to first-line chemotherapy
    Butaney, Mohit
    Porter, Jennifer
    Lindeman, Neal Ian
    Janne, Pasi A.
    Rabin, Michael S.
    Marcoux, J. Paul
    Johnson, Bruce E.
    Jackman, David Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] Influence of baseline inflammatory markers on the response to first-line chemotherapy in advanced NSCLC
    MacDonald, N.
    Kasymjanova, G.
    Agulnik, J. S.
    Pepe, C.
    Kreisman, H.
    Cohen, V.
    Sharma, R.
    Gagnon, B.
    Small, D.
    EJC SUPPLEMENTS, 2007, 5 (04): : 385 - 385
  • [47] CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC
    Wang, J.
    Wang, Z.
    Wu, L.
    Li, B.
    Cheng, Y.
    Li, X.
    Wang, X.
    Han, L.
    Wu, X.
    Fan, Y.
    Yu, Y.
    Lv, D.
    Shi, J.
    Huang, J.
    Zhou, S.
    Han, B.
    Sun, G.
    Guo, Q.
    Ji, Y.
    Zhu, X.
    Hu, S.
    Zhang, W.
    Wang, Q.
    Jia, Y.
    Wang, Z.
    Song, Y.
    Wu, J.
    Shi, M.
    Li, X.
    Han, Z.
    Liu, Y.
    Yu, Z.
    Liu, A.
    Wang, X.
    Zhou, C.
    Zhong, D.
    Miao, L.
    Zhang, Z.
    Zhao, H.
    Yang, J.
    Wang, D.
    Wang, Y.
    Li, Q.
    Zhang, X.
    Ji, M.
    Yang, Z.
    Cui, J.
    Gao, B.
    Wang, B.
    Liu, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S927 - S928
  • [48] SELECT-3: A phase I study of selumetinib in combination with platinumdoublet chemotherapy for advanced NSCLC in the first-line setting
    Dean, E.
    Steele, N.
    Arkenau, H-T.
    Blackhall, F.
    Haris, N. M.
    Lindsay, C.
    Rafii, S.
    Califano, R.
    Plummer, R.
    Voskoboynik, M.
    Summers, Y. J.
    Ghiorghiu, D.
    Dymond, A.
    So, K.
    Greystoke, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [49] Bevacizumab plus chemotherapy extends survival of patients with first-line nonsquamous NSCLC
    不详
    ONCOLOGY-NEW YORK, 2005, 19 (04): : 473 - 473
  • [50] First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation
    Yanjuan Xiong
    Lu Wang
    Weihong Zhang
    Yuan Meng
    Yang Wang
    Meng Shen
    Li Zhou
    Runmei Li
    Yingge Lv
    Shengguang Wang
    Xiubao Ren
    Liang Liu
    BMC Cancer, 24 (1)
12345